Richmond Pharmacology visits Japan to expand business

Originally published in Nikkan Yakugyo and Japan Medicine.

Jörg Täubel, CEO of Richmond Pharmacology (RPL) – a major British CRO – announced that he is aiming to expand business with pharmaceutical companies based in Japan (including companies with foreign capital affiliation). RPL's sales totaled 10 million pounds last fiscal year, and 25% of this comes from companies based in Japan. The company's sales estimate for this fiscal year is 11 million pounds, and the portion of Japanese based companies is expected to stay the same (25%). Mr. Täubel stated that, “(although, there has been no official discussion yet) we would like to eventually build a partnership with Bellsystem24, a Japanese CRO.”RPL is well regarded for its “bridging studies” of Caucasians and Japanese. 80 Japanese volunteers register for the company's clinical trial every month, most of whom are students studying English. RPL has Japanese doctors and nurses attend to the clinical trials for Japanese volunteers in order to eliminate language problems.RPL currently has contracts with 10 companies that are based in Japan (including companies with foreign capital affiliation). Dr. Täubel is planning on holding business meetings with 8 major companies (including current business partners) between Dec 5th and 11th.